Johns Hopkins ABX Guide
Nevirapine
INDICATIONS
FDA
FDA
- Treatment of HIV infection in combination with other antiretroviral agents.
- Due to increased risk of hepatitis, avoid starting NVP in women with pre-treatment CD4 >250 and men with CD4 >400.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- Single dose at time of delivery to prevent perinatal transmission (widely used in developing countries, but risk of NNRTI resistance; combination therapy preferred when available). Risk of hepatitis for women with CD4 >250 does not apply to single dose NVP.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: June 27, 2014
Citation
Pham, Paul A, et al. "Nevirapine." Johns Hopkins ABX Guide, The Johns Hopkins University, 2014. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540383/all/Nevirapine.
Pham PA, Bartlett JG, Hsu A . Nevirapine. Johns Hopkins ABX Guide. The Johns Hopkins University; 2014. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540383/all/Nevirapine. Accessed June 9, 2023.
Pham, P. A., Bartlett, J. G., & Hsu, A. . (2014). Nevirapine. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540383/all/Nevirapine
Pham PA, Bartlett JG, Hsu A . Nevirapine [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2014. [cited 2023 June 09]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540383/all/Nevirapine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Nevirapine
ID - 540383
A1 - Pham,Paul,Pharm.D.
AU - Bartlett,John,M.D.
AU - Hsu,Alice,Pharm.D.
Y1 - 2014/06/27/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540383/all/Nevirapine
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
